Literature DB >> 31183682

LncRNA TUG1 contributes to cardiac hypertrophy via regulating miR-29b-3p.

Xue Zou1, Jialiang Wang1, Li Tang1, Qian Wen2.   

Abstract

Cardiac hypertrophy with maladjusted cardiac remodeling is the leading cause of heart failure. In the past decades, long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) have been proved to exert multiple functions in cellular biological behaviors; however, their role in cardiac hypertrophy remains largely unclear. Presently, we first obtained hypertrophic H9c2 cells by treating with angiotensin II (Ang II) and uncovered upregulation of lncRNA taurine upregulated gene 1 (TUG1) in such H9c2 cells. Then, we demonstrated that silencing TUG1 attenuated Ang II-induced cardiac hypertrophy. Besides, a strong interactivity of TUG1 with miR-29b-3p at the putative sites was validated, suggesting that TUG1 was an endogenous sponge of miR-29b-3p in H9c2 cells. Additionally, the expression of miR-29b-3p was strikingly reduced by TUG1 upregulation and also inhibited under Ang II treatment, whereas it was restored after silencing TUG1 in hypertrophic cells. Also, we proved miR-29b-3p as a negative regulator in cardiac hypertrophy. Finally, miR-29b-3p inhibition abolished the anti-hypertrophy effect of TUG1 depletion in Ang II-treated H9c2 cells. Collectively, our findings confirmed that TUG1 functioned as a positive modulator of cardiac hypertrophy via sponging miR-29b-3p, indicating that TUG1 might serve as a potential target for the treatment of cardiac hypertrophy and even heart failure.

Entities:  

Keywords:  Ang II; Cardiac hypertrophy; H9c2 cells; TUG1; miR-29b-3p

Mesh:

Substances:

Year:  2019        PMID: 31183682     DOI: 10.1007/s11626-019-00368-x

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN: 1071-2690            Impact factor:   2.416


  38 in total

Review 1.  Long non-coding RNAs: insights into functions.

Authors:  Tim R Mercer; Marcel E Dinger; John S Mattick
Journal:  Nat Rev Genet       Date:  2009-03       Impact factor: 53.242

Review 2.  Long noncoding RNAs and microRNAs in cardiovascular pathophysiology.

Authors:  Thomas Thum; Gianluigi Condorelli
Journal:  Circ Res       Date:  2015-02-13       Impact factor: 17.367

Review 3.  Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.

Authors:  Bianca C Bernardo; Kate L Weeks; Lynette Pretorius; Julie R McMullen
Journal:  Pharmacol Ther       Date:  2010-05-12       Impact factor: 12.310

Review 4.  Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets.

Authors:  Abhinav Diwan; Gerald W Dorn
Journal:  Physiology (Bethesda)       Date:  2007-02

Review 5.  The multilayered complexity of ceRNA crosstalk and competition.

Authors:  Yvonne Tay; John Rinn; Pier Paolo Pandolfi
Journal:  Nature       Date:  2014-01-16       Impact factor: 49.962

6.  Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo.

Authors:  Tao Yang; Haihua Gu; Xiaofan Chen; Shaozhi Fu; Cheng Wang; Hongfei Xu; Qiang Feng; Yiming Ni
Journal:  J Surg Res       Date:  2014-07-02       Impact factor: 2.192

7.  MicroRNA-133 controls cardiac hypertrophy.

Authors:  Alessandra Carè; Daniele Catalucci; Federica Felicetti; Désirée Bonci; Antonio Addario; Paolo Gallo; Marie-Louise Bang; Patrizia Segnalini; Yusu Gu; Nancy D Dalton; Leonardo Elia; Michael V G Latronico; Morten Høydal; Camillo Autore; Matteo A Russo; Gerald W Dorn; Oyvind Ellingsen; Pilar Ruiz-Lozano; Kirk L Peterson; Carlo M Croce; Cesare Peschle; Gianluigi Condorelli
Journal:  Nat Med       Date:  2007-04-29       Impact factor: 53.440

Review 8.  Cardiac hypertrophy: the good, the bad, and the ugly.

Authors:  N Frey; E N Olson
Journal:  Annu Rev Physiol       Date:  2003-01-09       Impact factor: 19.318

9.  Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling.

Authors:  Ioannis Karakikes; Antoine H Chaanine; Soojeong Kang; Bertrand N Mukete; Dongtak Jeong; Shihong Zhang; Roger J Hajjar; Djamel Lebeche
Journal:  J Am Heart Assoc       Date:  2013-04-23       Impact factor: 5.501

10.  Regulatory Roles for Long ncRNA and mRNA.

Authors:  Armen R Karapetyan; Coen Buiting; Renske A Kuiper; Marcel W Coolen
Journal:  Cancers (Basel)       Date:  2013-04-26       Impact factor: 6.639

View more
  7 in total

1.  LncRNA TUG1 aggravates cardiomyocyte apoptosis and myocardial ischemia/reperfusion injury.

Authors:  Dongliang Fu; Tong Gao; Mengru Liu; Chunyan Li; Haiwei Li; Hong Jiang; Xianlun Fu
Journal:  Histol Histopathol       Date:  2021-10-20       Impact factor: 2.303

2.  lncRNA NBR2 attenuates angiotensin II-induced myocardial hypertrophy through repressing ER stress via activating LKB1/AMPK/Sirt1 pathway.

Authors:  Cansheng Zhu; Min Wang; Xianguan Yu; Xing Shui; Leile Tang; Zefeng Chen; Zhaojun Xiong
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  MiR-29b-3p aggravates cardiac hypoxia/reoxygenation injury via targeting PTX3.

Authors:  Dan He; Lei Yan
Journal:  Cytotechnology       Date:  2021-01-05       Impact factor: 2.058

4.  SP1-induced SNHG14 aggravates hypertrophic response in in vitro model of cardiac hypertrophy via up-regulation of PCDH17.

Authors:  Yadong Long; Lin Wang; Zhiqiang Li
Journal:  J Cell Mol Med       Date:  2020-05-21       Impact factor: 5.310

5.  Long Noncoding RNA FTX Reduces Hypertrophy of Neonatal Mouse Cardiac Myocytes and Regulates the PTEN/PI3K/Akt Signaling Pathway by Sponging MicroRNA-22.

Authors:  Xiaoyu Yang; Lichan Tao; Jin Zhu; Sheng Zhang
Journal:  Med Sci Monit       Date:  2019-12-16

6.  Knockdown of TUG1 rescues cardiomyocyte hypertrophy through targeting the miR-497/MEF2C axis.

Authors:  Guorong Zhang; Xinghua Ni
Journal:  Open Life Sci       Date:  2021-03-16       Impact factor: 0.938

Review 7.  Emerging roles of the RNA modifications N6-methyladenosine and adenosine-to-inosine in cardiovascular diseases.

Authors:  Vilbert Sikorski; Antti Vento; Esko Kankuri
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-20       Impact factor: 10.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.